European Commission logo
français français
CORDIS - Résultats de la recherche de l’UE
CORDIS

Health Initiatives in Psoriasis and PsOriatic arthritis ConsoRTium European States

Description du projet

Améliorer le diagnostic et la prise en charge de l’arthrite psoriasique

Le psoriasis est une maladie auto-immune de la peau associée à l’apparition de plaques rouges, sèches et qui démangent, siégeant surtout sur les coudes, les genoux et le cuir chevelu. Certains patients atteints de psoriasis développent un type d’arthrite inflammatoire appelée «arthrite psoriasique», susceptible de provoquer le gonflement et la rigidité des articulations. Toutefois, le diagnostic de l’arthrite psoriasique est difficile à poser, et il n’existe aucun moyen de prédire quels patients développeront la maladie ou comment ils répondront au traitement. HIPPOCRATES est un projet de grande ampleur, financé par l’UE, qui réunit des experts de la recherche, de la pratique clinique et de l’industrie afin de déterminer les mécanismes du développement et l’évolution de l’arthrite psoriasique. Les résultats du projet contribueront aux efforts futurs en matière de découverte des médicaments pour améliorer la prise en charge de la maladie et les résultats des patients.

Objectif

Psoriatic Arthritis (PsA) is a clinically heterogeneous disease associated with diminished quality of life. Early diagnosis is challenging and prediction of natural history or therapeutic response to treatment is suboptimal: these represent critical, contemporary unmet clinical needs. HIPPOCRATES is a multi-centre consortium, with 26 world-class partners that have clinical, scientific, data analytics, ethics, patient participation and pharmaceutical industry expertise. We will address these needs. Clinical phenotypic data from multiple established, and de novo PsA cohorts combined with a unique library of bio- samples, images, and data derived therefrom, will be curated and catalogued for optimal evaluation and use. HIPPOCRATES will analyse these multi-structured datasets that traverse the disease timeline, from cutaneous psoriasis, early PsA, first therapeutic and first biologic choice. Through machine learning and other AI techniques, we will: (1) Identify molecular signals associated with the development of PsA in patients with psoriasis, so presaging PsA prevention studies; (2) Create a diagnostic algorithm for early PsA diagnosis in patients with cutaneous psoriasis or early undifferentiated inflammatory arthritis; (3) Generate biomarker algorithms, including clinical, imaging and molecular polyomic moieties, to predict disease progression and identify endotypes permitting precision treatment with existing (methotrexate, and TNF or IL-17 inhibitor) treatments and novel therapeutic regimes; (4) Elucidate the molecular basis of PsA to facilitate future drug discovery; (5) Develop diagnostic digital tools for use in clinical settings. With highly aligned academic/clinical, SME and EFPIA partners, including involvement from existing IMI programmes and competitive international associations, HIPPOCRATES will oversee the development of a sustainable infrastructure to support PsA research and improve PsA patient outcomes.

Coordinateur

UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN
Contribution nette de l'UE
€ 1 492 441,25
Adresse
BELFIELD
4 Dublin
Irlande

Voir sur la carte

Région
Ireland Eastern and Midland Dublin
Type d’activité
Higher or Secondary Education Establishments
Liens
Coût total
€ 2 058 302,81

Participants (28)